Growth Metrics

Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2025)

Ultragenyx Pharmaceutical has reported Goodwill & Intangibles over the past 9 years, most recently at $220.0 million for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 0.9% to $220.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220.0 million through Dec 2025, down 0.9% year-over-year, with the annual reading at $220.0 million for FY2025, 0.9% down from the prior year.
  • Goodwill & Intangibles was $220.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $217.3 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $222.0 million in Q4 2024 and troughed at $175.3 million in Q3 2021.
  • The 5-year median for Goodwill & Intangibles is $206.3 million (2022), against an average of $203.8 million.
  • Year-over-year, Goodwill & Intangibles rose 18.5% in 2022 and then fell 0.9% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $175.7 million in 2021, then increased by 18.5% to $208.2 million in 2022, then grew by 4.8% to $218.2 million in 2023, then grew by 1.75% to $222.0 million in 2024, then decreased by 0.9% to $220.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Goodwill & Intangibles are $220.0 million (Q4 2025), $217.3 million (Q3 2025), and $219.1 million (Q2 2025).